Brazil
The Brazilian vehicle fleet reached 64.8 million vehicles in 2010, up from 29.5 million units in 2000, representing a 119% growth in ten years, and reaching a motorization rate of 340 vehicles per 1000 people. In 2010 Brazil experienced the second largest fleet increase in the world after China, with 2.5 million vehicle registrations.As of 2018, Brazil has the largest alternative fuel vehicle fleet in the world with about 40 million alternative fuel motor vehicles in the road. The clean vehicle stock includes 30.5 million flexible-fuel cars and light utility vehicles and over 6 million flex-fuel motorcycles by March 2018; between 2.4 and 3.0 million neat ethanol vehicles still in use, out of 5.7 million ethanol only light-vehicles produced since 1979; and, as of December 2012, a total of 1.69 million natural gas vehicles.In addition, all the Brazilian gasoline-powered fleet is designed to operate with high ethanol blends, up to 25% ethanol fuel (E25). The market share of flex fuel vehicles reached 88.6% of all light-duty vehicles registered in 2017. India
Indias vehicle fleet had the second-largest growth rate after China in 2010, with 8.9%. The fleet went from 19.1 million in 2009 to 20.8 million units in 2010. Indias vehicle fleet has increased to 210 million in March 2015. India has a fleet of 1.1 million natural gas vehicles 
as of December 2011 .
Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura and thrombosis.This drug was developed by Ablynx NV. On 30 August 2018, it was approved in the European Union for the "treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression".It is an anti-von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported.In February 2019, caplacizumab-yhdp (Cablivi, Ablynx NV) was approved in the United States for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). The drug is used in combination with plasma exchange and immunosuppressive therapy. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. References
External links
"Caplacizumab". Drug Information Portal. U.S. National Library of Medicine.